CONTEXT: The underlying molecular alterations causing sporadic parathyroid adenomas that drive primary hyperparathyroidism have not been thoroughly defined. OBJECTIVE: The aim of the study was to investigate the occurrence of somatic mutations driving tumor formation and progression in sporadic parathyroid adenoma using whole-exome sequencing. DESIGN: Eight matched tumor-constitutional DNA pairs from patients with sporadic parathyroid adenomas underwent whole-exome capture and high-throughput sequencing. Selected genes were analyzed for mutations in an additional 185 parathyroid adenomas. RESULTS: Four of eight tumors displayed a frame shift deletion or nonsense mutation in MEN1, which was accompanied by loss of heterozygosity of the remaining wild-type allele. No other mutated genes were shared among the eight tumors. One tumor harbored a Y641N mutation of the histone methyltransferase EZH2 gene, previously linked to myeloid and lymphoid malignancy formation. Targeted sequencing in the additional 185 parathyroid adenomas revealed a high rate of MEN1 mutations (35%). Furthermore, this targeted sequencing identified an additional parathyroid adenoma that contained the identical, somatic EZH2 mutation that was found by exome sequencing. CONCLUSION: This study confirms the frequent role of the loss of heterozygosity of chromosome 11 and MEN1 gene alterations in sporadic parathyroid adenomas and implicates a previously unassociated methyltransferase gene, EZH2, in endocrine tumorigenesis.
CONTEXT: The underlying molecular alterations causing sporadic parathyroid adenomas that drive primary hyperparathyroidism have not been thoroughly defined. OBJECTIVE: The aim of the study was to investigate the occurrence of somatic mutations driving tumor formation and progression in sporadic parathyroid adenoma using whole-exome sequencing. DESIGN: Eight matched tumor-constitutional DNA pairs from patients with sporadic parathyroid adenomas underwent whole-exome capture and high-throughput sequencing. Selected genes were analyzed for mutations in an additional 185 parathyroid adenomas. RESULTS: Four of eight tumors displayed a frame shift deletion or nonsense mutation in MEN1, which was accompanied by loss of heterozygosity of the remaining wild-type allele. No other mutated genes were shared among the eight tumors. One tumor harbored a Y641N mutation of the histone methyltransferase EZH2 gene, previously linked to myeloid and lymphoid malignancy formation. Targeted sequencing in the additional 185 parathyroid adenomas revealed a high rate of MEN1 mutations (35%). Furthermore, this targeted sequencing identified an additional parathyroid adenoma that contained the identical, somatic EZH2 mutation that was found by exome sequencing. CONCLUSION: This study confirms the frequent role of the loss of heterozygosity of chromosome 11 and MEN1 gene alterations in sporadic parathyroid adenomas and implicates a previously unassociated methyltransferase gene, EZH2, in endocrine tumorigenesis.
Authors: Murim Choi; Ute I Scholl; Peng Yue; Peyman Björklund; Bixiao Zhao; Carol Nelson-Williams; Weizhen Ji; Yoonsang Cho; Aniruddh Patel; Clara J Men; Elias Lolis; Max V Wisgerhof; David S Geller; Shrikant Mane; Per Hellman; Gunnar Westin; Göran Åkerström; Wenhui Wang; Tobias Carling; Richard P Lifton Journal: Science Date: 2011-02-11 Impact factor: 47.728
Authors: C Stewart; F Parente; F Piehl; F Farnebo; D Quincey; G Silins; L Bergman; G F Carle; I Lemmens; S Grimmond; C Z Xian; S Khodei; B T Teh; J Lagercrantz; P Siggers; A Calender; V Van de Vem; K Kas; G Weber; N Hayward; P Gaudray; C Larsson Journal: Oncogene Date: 1998-11-12 Impact factor: 9.867
Authors: Judy S Crabtree; Peter C Scacheri; Jerrold M Ward; Sara R McNally; Gary P Swain; Cristina Montagna; Jeffrey H Hager; Douglas Hanahan; Helena Edlund; Mark A Magnuson; Lisa Garrett-Beal; A Lee Burns; Thomas Ried; Settara C Chandrasekharappa; Stephen J Marx; Allen M Spiegel; Francis S Collins Journal: Mol Cell Biol Date: 2003-09 Impact factor: 4.272
Authors: Lee F Starker; Jessica Svedlund; Robert Udelsman; Henning Dralle; Göran Akerström; Gunnar Westin; Richard P Lifton; Peyman Björklund; Tobias Carling Journal: Genes Chromosomes Cancer Date: 2011-06-02 Impact factor: 5.006
Authors: Gijs van Haaften; Gillian L Dalgliesh; Helen Davies; Lina Chen; Graham Bignell; Chris Greenman; Sarah Edkins; Claire Hardy; Sarah O'Meara; Jon Teague; Adam Butler; Jonathan Hinton; Calli Latimer; Jenny Andrews; Syd Barthorpe; Dave Beare; Gemma Buck; Peter J Campbell; Jennifer Cole; Simon Forbes; Mingming Jia; David Jones; Chai Yin Kok; Catherine Leroy; Meng-Lay Lin; David J McBride; Mark Maddison; Simon Maquire; Kirsten McLay; Andrew Menzies; Tatiana Mironenko; Lee Mulderrig; Laura Mudie; Erin Pleasance; Rebecca Shepherd; Raffaella Smith; Lucy Stebbings; Philip Stephens; Gurpreet Tang; Patrick S Tarpey; Rachel Turner; Kelly Turrell; Jennifer Varian; Sofie West; Sara Widaa; Paul Wray; V Peter Collins; Koichi Ichimura; Simon Law; John Wong; Siu Tsan Yuen; Suet Yi Leung; Giovanni Tonon; Ronald A DePinho; Yu-Tzu Tai; Kenneth C Anderson; Richard J Kahnoski; Aaron Massie; Sok Kean Khoo; Bin Tean Teh; Michael R Stratton; P Andrew Futreal Journal: Nat Genet Date: 2009-03-29 Impact factor: 38.330
Authors: Brian Harding; Manuel C Lemos; Anita A C Reed; Gerard V Walls; Jeshmi Jeyabalan; Michael R Bowl; Hilda Tateossian; Nicky Sullivan; Tertius Hough; William D Fraser; Olaf Ansorge; Michael T Cheeseman; Rajesh V Thakker Journal: Endocr Relat Cancer Date: 2009-07-20 Impact factor: 5.678
Authors: Jessica Costa-Guda; Yasuo Imanishi; Nallasivam Palanisamy; Norihiko Kawamata; H Phillip Koeffler; R S K Chaganti; Andrew Arnold Journal: Endocrine Date: 2013-02-24 Impact factor: 3.633
Authors: Robert Romano; Chen-Pang Soong; Madison Rose; Jessica Costa-Guda; Justin Bellizzi; Andrew Arnold Journal: Endocrine Date: 2016-10-14 Impact factor: 3.633
Authors: Jessica Costa-Guda; Chen-Pang Soong; Vaishali I Parekh; Sunita K Agarwal; Andrew Arnold Journal: Horm Cancer Date: 2013-05-29 Impact factor: 3.869